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Abstract: Stemness in sarcomas is coordinated by the expression of pluripotency factors, like SOX2, 
in cancer stem cells (CSC). The role of SOX2 in tumor initiation and progression has been well 
characterized in osteosarcoma. However, the pro-tumorigenic features of SOX2 have been scarcely 
investigated in other sarcoma subtypes. Here, we show that SOX2 depletion dramatically reduced 
the ability of undifferentiated pleomorphic sarcoma (UPS) cells to form tumorspheres and to initiate 
tumor growth. Conversely, SOX2 overexpression resulted in increased in vivo tumorigenicity. 
Moreover, using a reporter system (SORE6) which allows to monitor viable cells expressing SOX2 
and/or OCT4, we found that SORE6+ cells were significantly more tumorigenic than the SORE6- 
subpopulation. In agreement with this findings, SOX2 expression in sarcoma patients was 
associated to tumor grade, differentiation, invasive potential and lower patient survival. Finally, we 
studied the effect of a panel of anti-tumor drugs on the SORE6+ cells of the UPS model and patient-
derived chondrosarcoma lines. We found that the mithramycin analogue EC-8042 was the most 
efficient in reducing SORE6+ cells in vitro and in vivo. Overall, this study demonstrates that SOX2 
is a pro-tumorigenic factor with prognostic potential in sarcoma. Moreover, SORE6 transcriptional 
activity is a bona fide CSC marker in sarcoma and constitutes an excellent biomarker for evaluating 
the efficacy of anti-tumor treatments on CSC subpopulations. 
Keywords: sarcoma; undifferentiated pleomorphic sarcoma; chondrosarcoma; SOX2; cancer stem 
cells; EC-8042 
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1. Introduction 
Similar to normal tissues, the cancer stem cell model proposes that tumors are hierarchically 
organized and at the apex of this structure there are cells presenting stem cell like properties (cancer 
stem cells, CSCs) able to self-renew and to differentiate and give rise to the rest of subpopulations 
present in the tumor [1]. Bona-fide CSCs are those subpopulations within the tumor with capacity to 
re-initiate tumor growth. Besides, they have enhanced ability to migrate and invade tissues and show 
increased resistance to chemotherapeutic drugs. A common characteristic of CSC subpopulations is 
the overexpression of transcription factors responsible for maintenance of the stem cell phenotype in 
embryonic and adult stem cells like SOX2 (Sex-determining region Y-box protein 2) or OCT4 
(POU5F1, POU Class 5 Homeobox 1) [2]. Subpopulations expressing these pluripotency factors have 
been correlated with tumor progression, drug resistance and the presence of hierarchically organized 
CSCs in several types of tumors [3–8]. In sarcomas, SOX2 has been found overexpressed in CSCs from 
different subtypes [9–18] and was described to play specific pro-tumorigenic roles in osteosarcoma 
[19–21]. In addition, OCT-4 expression was also associated to CSCs subpopulations in Ewing sarcoma 
and osteosarcoma [22,23]. 
To unequivocally confirm a given factor as a marker for CSCs, the subpopulation of tumor cells 
expressing it and/or presenting its associated activity must be isolated and demonstrate a higher 
tumorigenicity in vivo than other subpopulations. Since pluripotency factors are intracellular 
molecules, the isolation of viable cells expressing these factors cannot be directly achieved using 
antibody-based flow cytometry. As an alternative method, the use of reporter systems where the 
expression of a fluorescent protein is driven by the SOX2 and/or OCT4 promoter or by SOX2/OCT4 
response elements has proved the tumor-propagating potential of cells expressing pluripotency 
factors in several tumor models [4,8,22,24–31]. Notably, this strategy allows the real-time tracking of 
CSCs and the study of their response to anti-tumor treatments or changes in tumor 
microenvironment. 
In a previous work, we developed cell-of-origin models of sarcoma based in the tumor 
transformation of human mesenchymal stem/stromal cells (MSCs) using relevant oncogenic events 
[32–34]. We found that self-renewed tumorspheres formed by these cells showed increased 
expression of several CSC-related genes, including SOX2. Furthermore, by comparing the 
tumorigenic properties of these models with those of their xenograft-derived cell lines, we found that 
SOX2 expression was progressively enhanced in CSC-enriched tumorspheres during sarcoma 
progression toward more aggressive phenotypes, hence highlighting its potential applicability as 
CSC marker in sarcomas [35]. To further and significantly extend these data, herein we introduced a 
reporter system to monitor the transcriptional activity due to SOX2 and/or OCT4 (SORE6) [29] in a 
model of undifferentiated pleomorphic sarcoma (UPS) and chondrosarcoma patient-derived cell 
lines thus analyzing for the first time the ability of isolated SOX2/OCT4-positive cells as tumor-
promoting CSCs in sarcoma. The results of this approach, together with those obtained by SOX2 
knockdown and overexpression, indicate that SOX2 expression/activity is a bona fide CSC marker in 
sarcoma. In addition, this reporter system constitutes an excellent approach for testing the 
effectiveness and mode of action of anti-tumor drugs on CSC subpopulations. 
2. Results 
2.1. SOX2 Expression in Sarcoma Tissue Specimens is Associated to Poor Prognosis and Survival. 
We aimed to investigate whether the expression of pluripotency factors such as SOX2 and OCT4 
in sarcoma patients is clinically relevant. SOX2 and OCT4 expression was analyzed by 
immunohistochemistry in a collection of tissue microarrays, including samples from 10 types of 
sarcomas. Nuclear SOX2 expression was detected in 25 (28.4%) sarcoma samples (Figure 1A and B).  
Importantly, SOX2 expression significantly correlated with higher tumor grade (p = 0.001), poor 
differentiation (p = 0.005), and the presence of vascular (p = 0.003) or lymphatic invasion (p = 0.005) 
(Figure 1B). Moreover, SOX2-negative cases showed a trend for a longer survival time when 
compared to those expressing this factor (80 months (CI 69-92) vs 42 months (CI 25-59), respectively; 
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HR 2,8; p = 0.07). The 5-year survival rate was 78% for negative cases and 38% for positive cases 
(Figure 1C). 
On the other hand, nuclear expression of OCT4 was only detected in 10 cases (11%) and all of 
them displayed weak staining (Figure S1A and B). We did not find any significant association 
between OCT4 expression and clinical parameters. However, a strong correlation between SOX2 and 
OCT4 expression was observed, all OCT4-positive cases were also positive for SOX2 expression 
(Figure S1B). 
In summary, we found that SOX2, but not OCT4, correlated with advanced tumor stages, 
aggressive phenotypes and poor prognosis in sarcoma patients. According to these data SOX2, rather 
than OCT4, might primarily play an active role in the initiation and progression of sarcomas. 
 
Figure 1. Immunohistochemical analysis of SOX2 expression in sarcoma patients and associations 
with clinical data. (A) Representative examples of the indicated types of sarcoma showing positive or 
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negative SOX2 staining. Scale bars: 200 or 500 μm (insets). (B) Distribution of sarcoma cases (N=88) 
according to their SOX2 expression level across categories of the indicated patient characteristics and 
tumor clinicopathologic parameters. p values are shown. (C) Kaplan-Meier cumulative survival 
curves categorized by SOX2 protein expression in the cohort of sarcoma patients. p-values were 
estimated using the log-rank test. 
2.2. SOX2 Is Required to Maintain the Tumorigenic Potential in Sarcoma Cells.  
To study the possible pro-tumorigenic role of SOX2 in sarcoma, we performed knockdown 
experiments in T-5H-O cells, a previously described cell-of-origin model of UPS [32–34]. First, we 
transduced T-5H-O cells with lentiviral particles carrying a doxycycline-inducible SOX2 shRNA and 
selected three clones (T-5H-O-Tet-shSOX2#1, #3 and #8) that showed efficient depletion of SOX2 
expression upon doxycycline treatment (Figure 2A and B). According to the reciprocal regulation of 
these pluripotency factors [2], SOX2-depleted cells also displayed reduced expression of OCT4 
(Figure S2). Consistent with the role of SOX2 in stemness, its depletion in all the clones significantly 
decreased tumorsphere formation (Figure 2C and D). More importantly, doxycycline treatment of 
mice inoculated with doxycycline-pretreated T-5H-O-Tet-shSOX2#8 cells, but not with parental T-
5H-O cells, was sufficient to prevent in vivo tumor growth (Figure 2E). In line with these results, we 
found a significant reduction in both the ability to form colonies in soft-agar, a surrogate in vitro 
transformation assay, and the capacity to grow as tumorspheres upon depletion of SOX2 expression 
in T5H-O cells using another, non-conditional, shRNA (Figure S3A–E) or a siRNA (Figure S3F-J).  
 
Figure 2. The depletion of SOX2 strongly reduced the tumorigenic potential of sarcoma cells. (A–B) 
Relative mRNA expression (A) and flow cytometry analysis (B) of SOX2 in three clones of T-5H-O 
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cells carrying a doxycycline-inducible SOX2 shRNA in the presence or absence of 2 μg/mL 
doxycycline for 48 h. (C and D) Average number of three independent experiments (C) and 
representative images (D) of tumorspheres formed by the parental T-5H-O cells transduced with 
control ShRNA or the T-5H-O clones carrying a doxycycline-inducible SOX2 shRNA in the presence 
or absence of 2 μg/mL doxycycline for 48 h. Scale bars = 200 μm. (E) T-5H-O and T-5H-O-Tet-SOX2-
C8 cells were pretreated as indicated with vehicle (DMSO) or 2 μg/mL doxycycline for 72 h prior to 
the subcutaneous inoculation of 1 × 104 cells in immunodeficient mice (n = 7 mice per series). Upon 
inoculation mice were treated daily with vehicle (saline) or doxycycline (50 mg/kg) via 
intraperitoneal. Tumor growth (mean volume) kinetics of each series are represented. Error bars 
represent the standard deviation and asterisks indicate statistically significant differences with control 
groups (*: p < 0.05, **: p < 0.005, ***: p < 0.0005; two-sided Student t test). 
To further confirm the SOX2-driven tumorigenic properties in sarcoma cells, we stably 
overexpressed SOX2 in T-5H-O cells using lentiviral particles for the expression of SOX2 cDNA 
(Figure 3A). SOX2 overexpression did not show any impact in the ability to form colonies in soft agar 
(Figure 3B and C) nor in the capacity to grow as tumorspheres (Figure 3D and E). Nevertheless, cells 
overexpressing SOX2 were more tumorigenic and grew tumors in immunodeficient mice 
significantly faster than controls cells (Figure 3F and G). Therefore, basal levels of SOX2 seems to be 
sufficient to efficiently promote clonal growth in vitro, however, certain microenviromental 
conditions present in the in vivo experiments might promote a long-term tumorigenic potential of 
those cells with higher expression of SOX2. 
 
Figure 3. The overexpression of SOX2 increased the tumorigenic potential of sarcoma cells. T-5H-0 
cells were stably transduced using lentiviral vector to express EGFP cDNA (cDNA Control) or human 
SOX2 cDNA (cDNA SOX2) sequences. (A) Western blotting analysis of SOX2 expression. (B and C) 
Quantification of the number of colonies formed (n = 3 independent experiments) (B) and 
representative images of soft agar assays (C) performed with control and SOX2-overexpressing cells. 
(D and E) Average number of tumorspheres generated in three independent experiments (D) and 
representative images of the indicated tumorsphere cultures (E). Scale bars = 100 μm. (F–H) 
Evaluation of tumor growth observed after the inoculation of 1 × 106 cells stably transfected with 
cDNA Control or cDNA SOX2 in immunodefficient mice. Tumor growth kinetics (F), tumor weights 
(G) and images of tumors at the end of the experiment (H) are presented. Error bars represent the 
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standard deviation and asterisks indicate statistically significant differences (*: p < 0.05 by two-sided 
Student t test). 
Taken together, the data from depletion and overexpression experiments suggest that SOX2 
expression plays an active role in the initiation and progression of sarcomas thereby emerging as a 
biologically and clinically relevant feature.  
2.3. SOX2 Activity Marks a Subpopulation of CSCs in Sarcoma 
To assess whether cells expressing pluripotency factors like SOX2 behave as a CSC 
subpopulation with increased tumor-promoting ability, we made use of a lentiviral-based reporter 
system in which a composite SOX2/OCT4 response element (SORE6) coupled to a minimal 
cytomegalovirus (CMV) promoter controls the expression of GFP fluorescent reporter gene.  
The inclusion of proteasome-targeting degron sequences in the reporter genes resulted in greater 
selectivity and temporal resolution [29]. This system allowed us to detect, monitor and isolate viable 
cells expressing transcriptionally active SOX2 and/or OCT4 by flow cytometry (Figure 4A) or live cell 
time-lapse microscopy (Figure 4B). Thus, we used these lentiviral construction to transduce T-5H-O 
cells, a patient-derived chrondrosarcoma primary cell line, CDS-17, and a cell line derived from a 
xenograft generated by CDS-17 cells, T-CDS-17, in order to generate lines with stable expression of 
the SORE6 construct (T-5H-O-SORE6-GFP, CDS-17-SORE6-GFP and T-CDS-17-SORE6-GFP) or its 
corresponding control without the SORE6 response element (T-5H-O-minCMV-GFP, CDS-17-
minCMV-GFP and T-CDS-17-minCMV-GFP) which have been used as gating controls in the flow 
cytometry analyses. First, we found that the T-5H-O-SORE6-GFP, CDS-17-SORE6-GFP and T-CDS-
17-SORE6-GFP cells displayed percentages of SORE6+ ranging between 20 and 40% (Figure 4A and 
B). Therefore, we use SORE6 activity to isolate SORE6+ and SORE6- subpopulations by flow 
cytometry in the three cell lines (Figure S4A–C). As expected, SORE6+ T-5H-O cells showed a 
significantly higher expression of SOX2 than the SORE6- subpopulation (Figure S4D and E). We also 
found that SORE6+ cells showed a much higher ability to form tumorspheres than SORE6- cells both 
in T-5H-O UPS cells (Figure 4C and D) and in CDS-17 and T-CDS17 chondrosarcoma cells (Figure 
S5). To study whether SORE6+ subpopulation was enriched in tumor-promoting cells, we inoculated 
1 × 104 cells of both T-5H-O SORE6- and SORE6+ subpopulations in immunodeficient mice and 
measured tumor formation over time. We observed tumor growth in the SORE6+ series as early as 
day 6 post-inoculation. On the other hand, SORE6- cells did not generate measurable tumor growth 
till day 15 after the inoculation and showed significant statistical differences in tumor volume with 
the SORE6+ series (Figure 4E). At the end-point, tumor weights confirmed that SORE6+ cells 
generated significantly larger tumors than those obtained from SORE6- cells (Figure 4F). To confirm 
and quantify the enrichment of the SORE6+ subpopulation in CSCs, we performed LDA comparing 
the ability of SORE6- and SORE6+ cells to initiate tumor growth in vivo. We found that SORE6+ cells 
produced tumors in all cases after the inoculation of 5000 or 1000 cells and in 2 out of 5 tumors (2/5) 
after the inoculation of 100 cells. On the other hand, SORE6- generated 5/5, 2/5 and 1/5 tumors after 
the injection of 5000, 1000 or 100 cells respectively (Figure 4G). Therefore, the tumor-initiation 
frequency (TIF) calculated using ELDA software was 7-fold higher in SORE6+ cells (1 tumor-initiating 
cell out of 185) compared to SORE6- cells (1 out of 1273) (Figure 4H). 
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Figure 4. SORE6 activity marks a subpopulation of CSCs in sarcoma. (A) Flow-cytometry analysis 
showing the level of SORE6+ cells in T-5H-O-SORE6-GFP, CDS17-SORE6-GFP and T-CDS17-SORE6-
GFP cultures or its corresponding minCMV-GFP control cells. (B) Fluorescence microscopy images 
showing cell subpopulations presenting GFP-associated SORE6 activity. Scale bars = 50 μm (C and 
D) Tumorsphere formation assay performed on SORE6
+
 and SORE6−cells. Representative images (C) 
and the quantification of number of tumorspheres generated in three independent experiments (D) 
are shown. Scale bars = 200 μm (E and F) In vivo tumor formation ability of SORE6+ and SORE6- 
subpopulations of T-5H-O-SORE6-GFP cells. (E) Tumor growth kinetics observed after inoculation of 
immunodeficient mice with 1 × 104 cells of each population (n = 8 mice per series). (F) Average tumor 
weight at the end of the experiment. (G and H) In vivo limit dilution assay (LDA) to evaluate the 
tumor forming potential of SORE6+ and SORE6- T-5H-O-SORE6-GFP cells. (G) Images of the tumors 
formed in both series upon the inoculation of 5000, 1000 or 100 cells. (H) Quantification of the 
frequency of tumor initiating (TIF) cells using the ELDA software. The number of mice that grew 
tumors after 4 weeks and total number of inoculated mice for each condition is indicated. Error bars 
represent the standard deviation and asterisks indicate statistically significant differences (*: p < 0.05 
by two-sided Student t test). 
These experiments suggest that high SOX2/OCT4 transcriptional activity, measured by SORE6 
activity, could be used as a surrogate marker for CSCs in sarcomas. 
2.4. SORE6 Response Element is a Valuable Tool to Monitor CSCs Response to Anti-tumor Treatments. 
Given its role as CSC marker, we aimed to test whether SORE6 activity could be useful to 
evaluate the effectivity of anti-tumor drugs to target CSCs subpopulations. Therefore, we studied the 
impact on the SORE6+ subpopulation of drugs used in the treatment of sarcomas, like doxorubicin, 
trabectedin and paclitaxel, as well as the mithramycin analog EC-8042 which has proven as highly 
efficacious in targeting CSCs in sarcoma [36].  
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The IC50 values of these drugs in T-5H-O-SORE6-GFP cells were 307, 0.66, 7, and 288 nM for 
doxorubicin, trabectedin, paclitaxel and EC-8042 respectively (Figure S6). According to these values 
we evaluated SORE6 activity in T-5H-O cells in dose-response experiments using concentrations of 
each drug that induced low, medium (≈IC60), and high toxicity after 48 h of treatment. In these 
experiments, EC-8042 was the most efficient drug to reduce the SORE6+ subpopulation, being able 
to induce a 75% decrease of SORE6+ cells with a concentration in the order of its IC60. On the other 
hand, the rest of drugs only induced a clear regression of the SORE6 subpopulation when the higher 
concentrations were used (Figure 5). In addition, time course analysis after the treatment with 
concentrations in the order of the IC60 values also confirmed the higher potential of EC-8042 to 
eradicate SORE6+ cells in comparison with doxorubicin, trabectedin and paclitaxel (Figure 6A–C). 
This strong ability of EC-8042 to target SORE6+ cells was also evident in dose-response and time-
course analysis performed in CDS-17-SORE6-GFP and T-CDS17-SORE6-GFP cells (Figure S7).  
 
Figure 5. Dose-response effect of anti-tumor drugs on SORE6 positive CSCs. (A and B) Representative 
flow cytometry analysis of SORE6+ population in untreated T5H-O-minCMV-GFP (gating control) 
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(A) or in T5H-O-SORE6-GFP cells treated with the indicated concentrations of EC-8042, trabectedin, 
doxorubicin or paclitaxel for 48 h (B). (C) Graph showing the mean ± standard deviation of three 
independent experiments. 
 
Figure 6. Differential effects of anti-tumor drugs on SORE6 positive cells. (A–C) Time course analysis 
of SORE+ cells during drug treatment. (A and B) Representative flow cytometry analysis of the 
SORE6+ population in untreated T5H-O-minCMV-GFP (gating control) (A) or in T5H-O-SORE6-GFP 
cells treated for with 0.5 μM EC-8042, 0.8 nM trabectedin, 0.5 μM doxorubicin or 10 nM paclitaxel for 
the indicated times (B). (C) Graph showing the mean ± standard deviation of three independent 
experiments. Asterisks indicate statistically significant differences with the EC-8042 series at 72 h (*: 
p < 0.05, **: p < 0.005; two-sided Student t test). (D and E) Biparametric flow cytometry analysis of 
SORE-GFP and active-caspase 3 levels. (D)  Representative analysis in untreated T5H-O-minCMV-
GFP (gating control, inset) or in T5H-O-SORE6-GFP cells treated with Trabectedin (0.8 nM) or EC-
8042 (0.5 μM) for the indicated times. (E) Graphic representation of three independent experiments 
(mean ± standard deviation). 
To better characterize the mechanism associated with the differential ability of these drugs to 
decrease SORE6+ cells, we simultaneously analyzed SORE6 activity and caspase-3 activation by flow 
cytometry in T-5H-O-SORE6-GFP cells treated with trabectedin or EC-8042. In these analyses we 
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found that trabectedin was an efficient inductor of apoptosis both in SORE6+ and SORE6- cells. In 
addition, we found that EC-8042-treatment sharply reduced the percentage of SORE6+ cells even 
before the apoptotic effect become evident (Figure 6D and E). These results suggest that both drugs 
were able to target CSCs subpopulations using different mechanisms. On one hand, trabectedin 
eliminated SORE6+ cells through the induction of apoptosis and, on the other hand, EC-8042 would 
be able to switch-off SORE6-related transcriptional activity, thus possibly affecting their CSC-
associated properties, prior to the induction of apoptosis. 
Next, we treated mice bearing T-5H-O-SORE6-GFP tumors with different drugs, using 
previously established treatment regimens [36–38], to evaluate their effect on SORE6+ cells in vivo. 
With the exception of paclitaxel, all drugs were able to significantly reduced tumor growth, being 
EC-8042 the most efficient treatment (Figure 7A and B). At the experimental end-point SORE6 activity 
was analyzed by flow cytometry in dissociated tumor cells. We found that EC-8042 was the only drug 
able to reduce the percentage and the fluorescence intensity of SORE6+ cells (Figure 7C–E). On the 
other hand, trabectedin or doxorubicin treatments produced a slight increase in the percentage of 
SORE6+ cells and fluorescence intensity, resulting in significant differences with the levels detected 
in EC-8042-treated tumors (Figure 7C–E). 
 
Figure 7. Evaluation of SORE6 activity after in vivo treatments. Mice with tumor xenografts 
established after the s.c. inoculation of 3 × 106 T-5H-O-SORE6-GFP cells were randomly assigned to 5 
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different groups (n = 5 per group) and treated i.v. with saline buffer (control), EC-8042 (18 mg/Kg; 
every 3/4 days up to 5 doses), trabectedin (0.15 mg/Kg; every 7 days up to 3 doses), doxorubicin (4 
mg/Kg; every 7 days up to 3 doses) or paclitaxel (20 mg/Kg; every 7 days up to 3 doses). (A) Curves 
representing the mean relative tumor volume (± SEM) of xenografts during the treatments. The timing 
of treatments is indicated, all mice received the last treatment on day 14 and tumors were extracted 
and analyzed on day 16. (B) Mean tumor weight (±SEM) at the end of the experiment. Asterisks 
indicate significantly different kinetics than the control series (*: p < .05, **: p < .005; one-way ANOVA). 
(C and D) Flow cytometry analysis of SORE6 activity in tumors collected and disaggregated 48 h after 
the last dose of the indicated treatments. Representative flow cytometry dot plots (C) and summary 
graphs representing the percentage of SORE6+ cells (mean ± standard deviation) (D) and the mean 
SORE-GFP fluorescence intensity (mean ± standard deviation) (E) are shown. Asterisks indicate 
statistically significant differences between series (*: p < 0.05, **: p < 0.005, ***: p < 0.0005; one-way 
ANOVA). 
Altogether, these results prove the usefulness of analyzing SORE6+ activity to evaluate the 
activity of anti-tumor drugs to target CSCs in sarcoma both in vitro and in vivo. 
3. Discussion 
Similar to hematological malignancies and other solid tumors, intra-tumor heterogeneity in 
sarcomas may be explained, at least in part, by the emergence of subpopulations of CSCs which guide 
tumor growth and dissemination. The stemness state in sarcomas is orchestrated by the expression 
of pluripotency factors such as OCT3/4, NANOG, KLF4, and SOX2 [12,13,16,18]. Among them, SOX2 
has been shown as a common CSC-related factor in different types of sarcoma [18,39]. The pro-
tumorigenic role of SOX2 has been particularly well described in osteosarcoma models. Knockdown 
of this factor in osteosarcoma cell lines or in the osteoblastic lineage of an osteosarcoma mouse model 
resulted in the loss of proliferative potential in vitro and a drastic reduction of tumor formation in 
vivo [19–21]. Besides osteosarcoma, clues for pro-stemness and/or pro-tumorigenic role for SOX2 has 
also been reported in Ewing sarcoma [40,41] and embryonal rhabdomyosarcoma [42]. In addition, 
the level of SOX2 expression in a panel of primary sarcoma cell lines have been positively correlated 
with the ability to grow tumors in immunodeficient mice [17]. In line with these previous works, our 
knockdown experiments further expand the findings regarding the key role of SOX2 in sustaining 
tumorigenicity to a model of UPS. In addition, we show that SOX2 overexpression, explored for the 
first time in sarcoma, also support the prominent role of SOX2 in sarcomagenesis. 
We found that SOX2 is expressed in 28% of an array of 88 sarcoma patients, being UPS, synovial 
sarcomas and Ewing sarcomas those presenting a higher percentage of positive cases in concordance 
with the results of previous reports [43,44]. In our series, SOX2 expression significantly correlated 
with tumor grade, poor differentiation, invasive potential and poor patient survival. Similar results 
have been recently reported for Ewing Sarcoma [43], thus reinforcing their key role in sarcoma 
development and disease progression. The clinical significance of OCT4 expression has been barely 
addressed in sarcomas. In our series of patient samples, a weak expression of OCT4 was only detected 
in a small subset of sarcoma samples (11%), being synovial sarcoma the subtype with a higher 
percentage of positive samples (56%). Even though OCT4 expression was not significantly correlated 
with any clinicopathologic parameter and showed no impact on patient survival in our cohort of 
sarcoma patients, we cannot discard that the analysis of larger series of patients could unravel a 
clinically relevant role for OCT4 in specific sarcoma subtypes.  
Given the relevant role of SOX2 in tumorigenicity, here we used the SORE6 system [29] to study 
whether those subpopulations showing SOX2/OCT4 transcriptional activity behave as bona-fide 
CSCs with higher tumor-initiating potential than other subpopulations. SOX2-based reporter systems 
were previously used to demonstrate the CSC phenotype of SOX2-expressing subpopulations in 
glioma, breast, prostate, bladder or head and neck cancers [4,8,24,26–31], although this strategy 
remained unexplored in sarcomas. In addition, a plasmid containing the human OCT4 promoter 
driving the expression of GFP was used to show that OCT4-expressing osteosarcoma cells were much 
more tumorigenic than OCT4 negative cells [22]. In line with these works, we found that SORE6+ 
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UPS cells displayed greater potential than SORE6- cells to form tumorspheres in vitro and to develop 
tumors in vivo, thus confirming their CSC phenotype. In addition, we also detected a 20% of SORE6+ 
cells in a low passaged patient-derived chondrosarcoma cell line (CDS-17). Interestingly, this 
percentage was increased to 40% upon growth of CDS17 cells in a immunodeficient mice (xenograft 
TCDS-17 line). Considering that T-CDS17 displayed increased aggressiveness (higher invasion and 
tumor formation ability) than CDS-17 cells [45], the increase in SORE6+ cells could respond to an 
increase of the CSC burden during tumor progression and adaptation to new microenvironments. 
Similar findings regarding the gain of aggressiveness upon in vivo tumor growth associated to an 
increase of CSC markers, such as ALDH activity or OCT4 expression, have also been described in 
different types of sarcoma [22,35,45,46]. These findings support that serial transplantation could 
represent an efficient way of enriching/selecting CSC subpopulations [18]. 
In previous studies, we have reported that drugs already approved for sarcoma treatment such as 
trabectedin and experimental compounds such the mythramycin analog EC-8042 were able to target CSC 
subpopulations (tumorsphere cultures and/or Aldefluor-positive cells) in sarcomas with a higher efficacy 
than doxorubicin [36,38]. Here we used the SORE6 system to analyze both in vitro and in vivo models the 
effectiveness of these drugs and other chemotherapeutics used to treat sarcomas such as doxorubicin and 
paclitaxel to target CSCs. EC-8042 was the most efficient drug to target SORE6+ cells in vitro. Noteworthy, 
the reduction of SORE6+ subpopulations after in vivo treatment with EC8042 was not so efficient as 
observed in vitro. We may speculate that this difference could be due to the pharmacokinetic behavior of 
drugs in cells and animal models and/or the influence of factors from the tumor microenvironment. 
Nevertheless, EC8042 was the only treatment able to reduce this subpopulation in vivo. After EC8042 
treatment, SORE6+ cells disappeared before apoptosis become evident, thus suggesting that EC-8042 was 
able to repress the expression of SOX2, as we previously observed in a related myxoid liposarcoma model 
[36]. According to this, it was reported that mithramycin was able to reduce in vivo proliferation of 
glioblastoma cells through the downregulation of SOX2 expression and its target genes [47]. Likewise, 
mithramycin was able to abrogate tumor growth in medulloblastoma by targeting SOX2-expressing CSCs 
[48]. Given that EC-8042 is 10-fold less toxic than mithramycin [49], it could represent a suitable 
therapeutic option to eliminate CSCs in sarcomas. 
Although trabectedin was not as selective as EC-8042 to eliminate SORE6+ cells, this drug proved to 
be an efficient apoptotic inductor in both SORE6- and SORE6+ subpopulations, similar to previous 
findings demonstrating its ability to eliminate tumorsphere and Aldefluor-positive cells in the same 
sarcoma model [38]. Therefore, our work show that different drugs may target CSCs in sarcoma using 
different mechanisms and also that the SORE6 system is a valuable tool to dynamically evaluate the 
activity of anti-tumor drugs to target CSCs in sarcoma as seen in other tumor types [29,30]. 
4. Materials and Methods  
4.1. Cell Culture, Drugs and Ethics Statement. 
The UPS cell line T-5H-O and the chondrosarcoma cell lines CDS-17 and T-CDS17 were 
previously characterized (Supplemental Information) [32–35,45]. Tumorsphere formation and soft 
agar colony formation assays were performed as previously described [35,36]. Cell suspensions were 
counted in a haemocytometer using tryplan blue staining to discard non-viable cells both for in vitro 
and in vivo experiments. The percentage of viable cells in all conditions was always higher than 95%. 
Trabectedin (PharmaMar, Madrid, Spain), paclitaxel (Selleckchem, Houston, TX, USA), doxorubicin 
(Sigma, St Louis, MO, USA) and EC-8042 (EntreChem, Oviedo, Spain) were prepared as described in 
Supplemental Information. All experimental protocols have been performed in accordance with 
institutional review board guidelines and were approved by the Institutional Ethics Committee of 
the Principado de Asturias (ref. 45/16). All samples and data from human origin were provided by 
the Principado de Asturias BioBank (PT17/0015/0023) after obtaining signed informed consent.  
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4.2. Lentiviral Constructions and Cell Transduction.  
Conditional depletion of SOX2 was achieved using a doxycycline-inducible system obtained 
from Addgene (Cambridge, MA, USA) (Tet-pLKO-puro-SOX2; plasmid 47540) [50]. In addition, we 
also used a PLKO.1 lentivirus shRNA vector targeted against SOX2 (TRCN0000085748) together with 
the corresponding empty shRNA vector as a negative control (Dharmacon Lafayette, CO, USA). As 
an alternative method to knockdown SOX2 expression we used a specific siRNA (Supplemental 
Information). The lentiviral constructions to overexpress SOX2 (pSin-EF2-SOX2-Pur; addgene 
plasmid 16577) or GFP (used as a control) (pSin-EF2-GFP-Pur) cDNAs were kindly donated by Maria 
dM. Vivanco (CIC bioGUNE, Derio, Spain). Lentiviral reporter systems in which a composite 
SOX2/OCT4 response element (SORE6) coupled to a minimal cytomegalovirus (mCMV) drive the 
expression of GFP (SORE6-mCMVp-dsCopGFP-Puro) and its corresponding control lacking SORE6 
(mCMVp-dsCopGFP-Puro) were previously generated and characterized [29] and were kindly 
donated by Dr. L.M. Wakefield (National Cancer Institute, Bethesda, MD, USA). Generation of 
lentiviral particles were performed as previously described [34]. Transduced cells were positively 
selected through a treatment with puromycin 30 mg/mL for 6 days. To achieve an inducible 
expression of SOX2 shRNA in vitro, cells were treated with 2 μg/mL of doxycycline (Sigma). 
4.3. Flow Cytometry and Cell Sorting 
The level of SORE6-driven GFP fluorescence in untreated cultures or after different drug 
treatments were analyzed and/or SORE6+ and SORE6- subpopulations were sorted by flow 
cytometry using a BD FACS Aria II Cell Sorter (BD Bioscience, Erembodegem, Belgium). Cells 
transduced with the minCMVp-GFP lentivirus were used as matched SORE6 negative control for 
gating purposes. In these analyses, dead cells were excluded by propidium iodide (0.5 μg/mL) 
staining (Figure S8). To analyze the induction of apoptosis in SORE6+ and SORE6- subpopulations, 
unfixed cells were assayed for active caspase-3 immediately after treatment using the PE Active 
Caspase-3 Apoptosis Kit (BD Bioscience) according to the manufacturer’s instructions and the level 
of GFP (SORE6) and PE (Caspase 3) fluorescence was simultaneously detected by flow cytometry. 
SOX2 and OCT4 expression was detected by flow cytometry in 70% ethanol-fixed cells using an anti-
SOX2 antibody from Thermo Fisher (Waltham, MA) (PA1-094); 1 : 1000 dilution) or anti-OCT4 
antibody from AbCam (Cambridge, UK) ((ab19857); 1 : 1000 dilution). 
4.4. Western Blotting 
Whole cell protein extraction and Western blot analysis were performed as previously described 
[36]. Antibodies used are described in Supplemental Information. Uncropped images of the Western 
Blottings are shown as in Figure S9. 
4.5. RT-qPCR Assays 
The expression of SOX2 was assessed by qPCR as described in Supplemental Information. 
4.6. In Vivo Tumor Growth 
Female NOD/SCID mice of 6-7 weeks old (Janvier Labs, St Berthevin, France) were inoculated 
subcutaneously (s.c.) as described [36]. In experiments aimed to evaluate the effect of anti-tumor 
drugs, mice with tumor xenografts with a volume of approximately 300 mm3 were randomly 
assigned to receive the following intravenous treatments: vehicle (saline, every 7 days up to 3 doses), 
EC-8042 (18 mg/Kg; every 3/4 days up to 5 doses), trabectedin (0.15 mg/Kg; every 7 days up to 3 
doses), doxorubicin (4 mg/Kg; every 7 days up to 3 doses) or paclitaxel (20 mg/Kg; every 7 days up 
to 3 doses). Treatment schedules were optimized according to the therapeutic window of the different 
drugs [36–38]. To analyze the effect of the conditional knockdown of SOX2, mice inoculated with cells 
expressing or not the Tet-pLKO-puro-SOX2 lentiviral vector received a daily intraperitoneal dose of 
doxycycline (50 mg/kg). Tumor size was measured with a caliper 2–3 times a week and tumor volume 
was determined using the equation (D × d2)/6 × 3.14, where D is the maximum diameter, and d is the 
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minimum diameter. Relative tumor volume (RTV) for every xenograft was calculated as follows: RTV 
= tumor volume at day of measurement (Vt) − tumor volume at the beginning of the treatment (V0). 
Tumor volumes, or RTV in drug-treated experiments, for all mice in each group were averaged to 
obtain the mean tumor volume for the corresponding group. Animals were sacrificed by CO2 
asphyxiation and tumors were weighted. To determine the effect of drugs on SORE6 activity, tumors 
were dissociated into single cell suspensions using MACS Tissue Dissociation Kit and the 
GentleMACS Dissociator system (Miltenyi Biotec, Bergisch Gladbach, Germany) and the SORE6-
positive subpopulations were quantified by flow cytometry. In limited dilution assays (LDA) animals 
were sacrificed 4 weeks after cells inoculation. In these experiments, relative tumor-initiating 
frequency (TIF) was calculated using the ELDA software. All experimental protocols were carried 
out in accordance with the institutional guidelines of the University of Oviedo and were approved 
by the Animal Research Ethical Committee of the University of Oviedo prior to the study (Ref. 
PROAE11/2014). 
4.7. Patients and Immunohistochemical Analysis 
Paraffin-embedded tissues from 90 patients with sarcoma who underwent resection of their 
tumors at the Hospital Universitario Central de Asturias (HUCA) were used in this study. Tumor 
grade was evaluated in H&E-stained preparations using the French Federation of Comprehensive 
Cancer Centers grading system (Supplemental Information). Tissue microarray was constructed as 
previously described [51]. Immunohistochemical analysis of SOX2 and OCT4 expression was 
performed as detailed in Supplemental Information. The immunostaining was scored blinded to 
clinical data by two independent observers as negative or positive nuclear staining (> 1% positive 
nuclei).  
4.8. Statistical Analysis 
For the in vitro experiments and the tumor growth experiment in vivo, the statistical analysis 
was performed using the GraphPad Prism software (GraphPad Software, Inc, La Jolla, CA, USA). All 
data are represented as mean (±SD or SEM as indicated) of at least three independent experiments 
unless otherwise stated. Student’s t test was performed to determine the statistical significance 
between groups. Multiple comparisons of the data were performed using the one-way ANOVA. For 
immunohistochemical analysis, the experimental results distributed among the different clinical 
groups of tumors were tested for significance employing the χ2 test (with Yates’ correction, when 
appropriate). Survival curves were calculated using the Kaplan-Meier product limit estimate. 
Differences between survival times were analyzed by the log-rank method and the Hazard Ratio was 
calculated by univariate Cox regression analysis. All statistical analysis was carried out with the 
software package SPSS 24 (SPSS, IBM corp). All tests were two-sided and p < 0.05 values were 
considered statistically significant. 
5. Conclusions 
Overall, our results indicate that SOX2 is a critical stemness factor able to increase the 
tumorigenic properties of sarcoma cells. Notably, SOX2 expression correlate with advanced-disease 
related parameters in patients, therefore, suggesting its possible usefulness as prognostic marker in 
sarcoma. Moreover, the transcriptional activity of SOX2 and/or OCT4, measured using the SORE6 
reporter, is a bona fide CSC marker in sarcoma and constitutes an excellent approach for testing the 
effectiveness of anti-tumor treatments to target CSCs. 
Supplementary Materials: The following are available online at www.mdpi.com/2072-6694/12/4/964/s1, 
Supplemental Materials and Methods, Figure S1: Immunohistochemical analysis of OCT4 expression in sarcoma 
patients and associations clinical data, Figure S2: OCT4 expression in SOX2-depleted cells, Figure S3: SOX2 
depletion inhibited colony formation in soft agar and tumorsphere growth, Figure S4: Flow cytometry sorting 
of SORE6 positive and negative subpopulations, Figure S5: Tumorsphere growth ability of SORE6+ and SORE6- 
subpopulations in CDS17 and T-CDS17 cell lines, Figure S6: Dose-response toxicity curves, Figure S7: Effect of 
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EC-8042 on the SORE6+ subpopulation of chondrosarcoma patient-derived cell lines, Figure S8: Gating strategy 
used to analyze SORE6 activity, Figure S9, Whole Western blotting images. 
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